Longevity science
Follow
Find tag "biomarkers"
66.4K views | +10 today
Longevity science
Live longer in good health and you will have a chance to extend your healthy life even further
Your new post is loading...
Your new post is loading...
Rescooped by Ray and Terry's from Lung Cancer Dispatch
Scoop.it!

Blood Protein Test Can Identify Lung Cancer Patients Likely to Benefit from Targeted Therapy

A recent phase III clinical trial confirmed that the VeriStrat test can predict which lung cancer patients are likely to fare better when treated with EGFR inhibitors like erlotinib (Tarceva). Patients with advanced non-small cell lung cancer (NSCLC) were tested using VeriStrat before beginning Tarceva treatment. Those who had a VeriStrat result of “Good” experienced longer times without cancer growth and longer overall survival on Tarceva compared to those with a “Bad” result. VeriStrat results may help doctors distinguish patients who should be given EGFR inhibitors from those for whom the benefits would not outweigh the side effects, and who would be better served by other treatments. VeriStrat does not test for mutations in the EGFR gene. Instead, the test assesses the pattern of several proteins in the blood to pinpoint patients likely to respond to EGFR inhibitors, including patients who may not have an EGFR mutation.


Via Cancer Commons
more...
Cancer Commons's curator insight, June 6, 2013 5:38 AM

Xconomy | June 3, 2013

Brian Shields's curator insight, June 6, 2013 8:18 PM

Some interesting data out of ASCO using protien signatures in the blood to help develop personalized medicine for lung cancer patients.  Article excerpt follows:

The results from the Phase 3 trial announced today, shows it can make that difference, in a prospective study, which means that patients got the Biodesix test, were treated based on its recommendation, and followed over time to see if they ended up any better off. Passing that kind of rigorous study, should greatly expands the commercial potential for VeriStrat, Brunel said.

“VeriStrat has been commercially available for several years, but adoption has been limited…. This could lead to widespread adoption,” Brunel said.

According to the American Cancer Society, about 220,000 Americans per year are diagnosed with lung cancer, and about 85-90 percent have non-small cell lung cancer.

Biodesix will now build a national sales team and develop its marketing to try to capitalize on VeriStrat’s commercial potential, which could improve as the federal government is expected to reach a decision soon about whether it will be covered by Medicare.

Rescooped by Ray and Terry's from Biomarkers and Personalized Medicine
Scoop.it!

New Biomarker May Allow Earlier Diagnosis of Mesothelioma

"Researchers have shown that the protein fibulin-3 may be able to distinguish patients with mesothelioma from people with similar conditions and from healthy individuals. Although preliminary, the results suggest that this protein may be a promising new biomarker for diagnosing the disease and possibly informing prognosis. The study was published October 11 in the New England Journal of Medicine.

 

Pleural mesothelioma, a disease of the tissue that lines the chest cavity and covers the lungs (the pleura), is an aggressive cancer often associated with asbestos exposure. Patients diagnosed with this disease have a median survival of 1 year.

 

Diagnosing mesothelioma early, when treatment may be most effective, is difficult because of its long latency period and the lack of reliable methods to detect the disease in its early stages. A protein called soluble mesothelin-related protein is the best-studied biomarker for mesothelioma, but the test for it has low sensitivity, meaning that it fails to detect mesothelioma in some people who have the disease.."


Via Brian Shields
more...
No comment yet.
Scooped by Ray and Terry's
Scoop.it!

GE Healthcare Launches its First “Next-Generation” Sequencing Assay | Biomarker Commons

GE Healthcare Launches its First “Next-Generation” Sequencing Assay | Biomarker Commons | Longevity science | Scoop.it

GE Healthcare recently announced that Clarient Diagnostic Services, Inc., a GE Healthcare company, will begin offering a next-generation sequencing assay focused on solid tumor targets for use in clinical trials. This assay will empower researchers to perform prospective and retrospective analysis to better understand which patients will respond to particular therapies, to help stratify patient populations for ongoing clinical trials, and to aid early research efforts.

more...
No comment yet.
Rescooped by Ray and Terry's from Biomarkers and Personalized Medicine
Scoop.it!

Poster: Mining PubMed for Biomarker-Disease Associations to Guide Discovery | Walter Jessen Discovery New Media

Poster: Mining PubMed for Biomarker-Disease Associations to Guide Discovery | Walter Jessen Discovery New Media | Longevity science | Scoop.it

This article highlights the power of the internet to help drive future biomarker research and drug discovery...Incredible innovation using very low cost tools


Via Brian Shields
more...
No comment yet.